MilliporeSigma

Executive Summary

MilliporeSigma, a private Swiss life science leader (founded 1951), provides one of the industry's broadest portfolios of antibodies, reagents, and CDMO services for pharmaceutical development and manufacturing. With a fully integrated service organization supporting traditional and novel modalities, the company enables scientists and biopharma partners to accelerate research and production. As a subsidiary of Merck KGaA, MilliporeSigma leverages deep expertise in biologics and small molecules, positioning itself as a critical enabler of drug innovation. The company's vast product catalog and end-to-end CDMO capabilities, from early development to commercial manufacturing, drive its competitive advantage. Despite being private, MilliporeSigma's influence in the life sciences ecosystem is substantial, with a focus on high-growth areas like cell and gene therapy, mRNA technologies, and specialty antibodies. Its Burlington, Switzerland headquarters anchors a global network that serves customers in over 190 countries. The company's commitment to quality and scalability underpins its long-term growth, supported by ongoing investments in capacity and technology to meet rising demand for outsourced pharma services and novel therapies.

Upcoming Catalysts (preview)

• Q3 2026Launch of novel antibody platform for cell therapy applications60% success
• Q1 2027Expansion of viral vector manufacturing capacity in Europe75% success
• Q4 2026Major CDMO contract win with a top-20 pharma company50% success